免疫原性
免疫系统
免疫疗法
下调和上调
癌症研究
免疫检查点
干扰素
免疫学
封锁
癌症
结直肠癌
癌症免疫疗法
生物
PD-L1
肿瘤进展
免疫
医学
先天免疫系统
信号转导
干扰素γ
细胞因子
抗体
肿瘤微环境
干扰素基因刺激剂
转录组
炎症
作者
Haoyue Liu,Jeong‐Hoon Jang,Fuduan Peng,Hajar Rajaei,Vidhi Chandra,Li Li,Dhwani N. Rupani,Sedigheh Taghinezhad‐S,Yuehui Zhao,Erika Y. Faraoni,Thais Fernanda Bartelli,Olivereen Le Roux,Virginia Tahan,Fernando Jimenez-Arancon,Seyda Baydogan,Amir Hossein Mohseni,Javier A. Gomez,Mitesh Patel,Jared K. Burks,Barbara Mino
标识
DOI:10.1158/2159-8290.cd-24-1908
摘要
Abstract Tumor microbes are increasingly recognized for modulating tumor behavior and therapy responses. Intratumoral microbial burden (ITMB) analysis across cancers revealed regulation of immune pathways, and activated mast cells, mostly in colorectal (CRC) and gastric (STAD) cancers. High ITMB CRC leads to interferon regulation and is associated with improved outcomes in advanced disease. Single-cell sequencing revealed induction of interferon-related genes (IRGs) within microbes-containing human CRC. GI-luminal mismatch repair deficiency (MMRd) tumors had higher ITMB than proficient tumors (MMRp). In a rectal MMRd cohort with 100% remission after immune checkpoint blockade (ICB), tumor microbes and microbes-containing mast cells increased. In ICB-sensitive syngeneic murine MMRd tumor models, local tumor microbial depletion, impaired ICB efficacy while downregulating IFN signaling. Forced upregulation of IRGs in ADAR1-deficient cancer cells restored immunotherapy responses during microbial ablation. These data highlight dynamic interplay between ITMB, host defense, and immunogenicity which seems key to determine therapy responses
科研通智能强力驱动
Strongly Powered by AbleSci AI